Presenilins and the γ-secretase: Still a complex problem

Molecular Brain

Volumn 3, Issue 1, 2010, Pages

  Small, David H ^a,b   Klaver, David W ^a,b   Foa, Lisa ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BETA SECRETASE 1; CALCIUM; GAMMA SECRETASE; PRESENILIN; SECRETASE;

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; CALCIUM HOMEOSTASIS; HUMAN; LOSS OF FUNCTION MUTATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; CELL MEMBRANE; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; CALCIUM; CELL MEMBRANE; HUMANS; MUTATION; PRESENILINS;

EID: 77950222812     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-3-7     Document Type: Review

References (51)

1. The neuropsychological diagnosis of Alzheimer's disease. E Storey GJ Kinsella MJ Slavin, J Alzheimers Dis 2001 3 261 285 12214048
2. Amyloid plaque core protein in Alzheimer disease and Down syndrome. CL Masters G Simms NA Weinman G Multhaup BL McDonald K Beyreuther, Proc Natl Acad Sci USA 1985 82 4245 4249 10.1073/pnas.82.12.4245 3159021
3. Regulation of APP cleavage by alpha-, beta- and gamma-secretases. J Nunan DH Small, FEBS Lett 2000 483 6 10 10.1016/S0014-5793(00)02076-7 11033346
4. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? JT Jarrett PT Lansbury Jr, Cell 1993 73 1055 1058 10.1016/0092-8674(93)90635-4 8513491
5. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics - relevance for Alzheimer's disease. T Muller HE Meyer R Egensperger K Marcus, Prog Neurobiol 2008 85 393 406 10.1016/j.pneurobio.2008.05.002 18603345
6. A beta oligomers - a decade of discovery. DM Walsh DJ Selkoe, J Neurochem 2007 101 1172 1184 10.1111/j.1471-4159.2006.04426.x 17286590
7. Alzheimer's disease genetics current status and future perspectives. L Bertram, Int Rev Neurobiol 2009 84 167 184 19501718
8. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. J Kang HG Lemaire A Unterbeck JM Salbaum CL Masters KH Grzeschik G Multhaup K Beyreuther B Muller-Hill, Nature 1987 325 733 736 10.1038/325733a0 2881207
9. Mapping of the gene encoding the beta-amyloid precursor protein and its relationship to the Down syndrome region of chromosome 21. D Patterson K Gardiner FT Kao R Tanzi P Watkins JF Gusella, Proc Natl Acad Sci USA 1988 85 8266 8270 10.1073/pnas.85.21.8266 2973063
10. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. A Goate MC Chartier-Harlin M Mullan J Brown F Crawford L Fidani L Giuffra A Haynes N Irving L James R Mant P Newton K Rooke P Roques C Talbot M Pericak-Vance A Roses R Williamson M Rossor M Owen J Hardy, Nature 1991 349 704 706 10.1038/349704a0 1671712
11. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. J Murrell M Farlow B Ghetti MD Benson, Science 1991 254 97 99 10.1126/science.1925564 1925564
12. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. MC Chartier-Harlin F Crawford H Houlden A Warren D Hughes L Fidani A Goate M Rossor P Roques J Hardy, et al. Nature 1991 353 844 846 10.1038/353844a0 1944558
13. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. M Mullan F Crawford K Axelman H Houlden L Lilius B Winblad L Lannfelt, Nat Genet 1992 1 345 347 10.1038/ng0892-345 1302033
14. Alzheimer disease: evidence for susceptibility loci on chromosomes 6 and 14. LR Weitkamp L Nee B Keats RJ Polinsky S Guttormsen, Am J Hum Genet 1983 35 443 453 6859040
15. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. R Sherrington EI Rogaev Y Liang EA Rogaeva G Levesque M Ikeda H Chi C Lin G Li K Holman, et al. Nature 1995 375 754 760 10.1038/375754a0 7596406
16. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. E Levy-Lahad W Wasco P Poorkaj DM Romano J Oshima WH Pettingell CE Yu PD Jondro SD Schmidt K Wang, et al. Science 1995 269 973 977 10.1126/science.7638622 7638622
17. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. EI Rogaev R Sherrington EA Rogaeva G Levesque M Ikeda Y Liang H Chi C Lin K Holman T Tsuda, et al. Nature 1995 376 775 778 10.1038/376775a0 7651536
18. Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. D Levitan I Greenwald, Nature 1995 377 351 354 10.1038/377351a0 7566091
19. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. L Bertram RE Tanzi, Nat Rev Neurosci 2008 9 768 778 10.1038/nrn2494 18802446
20. Presenilin-1 is processed into two major cleavage products in neuronal cell lines. RV Ward JB Davis CW Gray AJ Barton LG Bresciani M Caivano VF Murphy K Duff M Hutton J Hardy, et al. Neurodegeneration 1996 5 293 298 10.1006/neur.1996.0040 9117540
21. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. D Scheuner C Eckman M Jensen X Song M Citron N Suzuki TD Bird J Hardy M Hutton W Kukull, et al. Nat Med 1996 2 864 870 10.1038/nm0896-864 8705854
22. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. J Shen RJ Kelleher, Proc Natl Acad Sci USA 2007 104 403 409 10.1073/pnas.0608332104 17197420
23. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. B De Strooper P Saftig K Craessaerts H Vanderstichele G Guhde W Annaert K Von Figura F Van Leuven, Nature 1998 391 387 390 10.1038/34910 9450754
24. Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. A Herreman L Serneels W Annaert D Collen L Schoonjans B De Strooper, Nat Cell Biol 2000 2 461 462 10.1038/35017105 10878813
25. Reconstitution of gamma-secretase activity. D Edbauer E Winkler JT Regula B Pesold H Steiner C Haass, Nat Cell Biol 2003 5 486 488 10.1038/ncb960 12679784
26. Candidate gamma-secretases in the generation of the carboxyl terminus of the Alzheimer's disease beta A4 amyloid: possible involvement of cathepsin D. G Evin R Cappai QX Li JG Culvenor DH Small K Beyreuther CL Masters, Biochemistry 1995 34 14185 14192 10.1021/bi00043a024 7578016
27. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease. D Beher SL Graham, Expert Opin Investig Drugs 2005 14 1385 1409 10.1517/13543784.14.11.1385 16255678
28. Therapeutic strategies for Alzheimer's disease. MS Wolfe, Nat Rev Drug Discov 2002 1 859 866 10.1038/nrd938 12415246
29. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. MS Wolfe W Xia BL Ostaszewski TS Diehl WT Kimberly DJ Selkoe, Nature 1999 398 513 517 10.1038/19077 10206644
30. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. WP Esler WT Kimberly BL Ostaszewski TS Diehl CL Moore JY Tsai T Rahmati W Xia DJ Selkoe MS Wolfe, Nat Cell Biol 2000 2 428 434 10.1038/35017062 10878808
31. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. YM Li M Xu MT Lai Q Huang JL Castro J DiMuzio-Mower T Harrison C Lellis A Nadin JG Neduvelil, et al. Nature 2000 405 689 694 10.1038/35015085 10864326
32. Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. ML Hemming JE Elias SP Gygi DJ Selkoe, PLoS Biol 2008 6 257 10.1371/journal.pbio.0060257 18942891
33. Gene expression profiling in cells with enhanced gamma-secretase activity. AI Magold M Cacquevel PC Fraering, PLoS One 2009 4 6952 10.1371/journal.pone.0006952 19763259
34. Therapeutic potential of gamma-secretase inhibitors and modulators. BP Imbimbo, Curr Top Med Chem 2008 8 54 61 10.2174/156802608783334015 18220933
35. Notch signalling: control of cell communication and cell fate. EC Lai, Development 2004 131 965 973 10.1242/dev.01074 14973298
36. Moonlighting activity of presenilin in plants is independent of -secretase and evolutionarily conserved. A Khandelwal D Chandu CM Roe R Kopan RS Quatrano, Proc Natl Acad Sci USA 2007 104 13337 13342 10.1073/pnas.0702038104 17684101
37. Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. P Osenkowski H Li W Ye D Li L Aeschbach PC Fraering MS Wolfe DJ Selkoe, J Mol Biol 2009 385 642 652 10.1016/j.jmb.2008.10.078 19013469
38. Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. VK Lazarov PC Fraering W Ye MS Wolfe DJ Selkoe H Li, Proc Natl Acad Sci USA 2006 103 6889 6894 10.1073/pnas.0602321103 16636269
39. Proteolysis as a regulatory mechanism. M Ehrmann T Clausen, Annu Rev Genet 2004 38 709 724 10.1146/annurev.genet.38.072902.093416 15568990
40. Crystal structure of a rhomboid family intramembrane protease. Y Wang Y Zhang Y Ha, Nature 2006 444 179 180 10.1038/nature05255 17051161
41. The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. R Wang D Sweeney SE Gandy SS Sisodia, J Biol Chem 1996 271 31894 31902 10.1074/jbc.271.50.31894 8943233
42. A novel epsilon-cleavage within the transmembrane domain of the amyloid precursor protein demonstrates homology with Notch processing. S Weidemann Eggert FB Reinhard M Vogel K Paliga G Baier CL Masters G Evin, Biochemistry 2002 41 2825 2835 10.1021/bi015794o 11851430
43. -Secretase catalyzes sequential cleavages of the A PP transmembrane domain. X Xu, J Alzheimer Dis 2009 16 211 224
44. Identification of the role of presenilins beyond Alzheimer's disease. G Thinakaran AT Parent, Pharmacol Res 2004 50 411 418 10.1016/j.phrs.2003.12.026 15304238
45. Gamma-secretase activity is not involved in presenilin-mediated regulation of beta-catenin. JE Meredith Jr Q Wang TJ Mitchell RE Olson R Zaczek AM Stern D Seiffert, Biochem Biophys Res Commun 2002 299 744 750 10.1016/S0006-291X(02)02747-X 12470641
46. The role of Abeta-induced calcium dysregulation in the pathogenesis of Alzheimer's disease. DH Small R Gasperini AJ Vincent AC Hung L Foa, J Alzheimers Dis 2009 16 225 233 19221414
47. Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. H Tu O Nelson A Bezprozvanny Z Wang SF Lee YH Hao L Serneels B De Strooper G Yu I Bezprozvanny, Cell 2006 126 981 993 10.1016/j.cell.2006.06.059 16959576
48. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. SL Chan M Mayne CP Holden JD Geiger MP Mattson, J Biol Chem 2000 275 18195 18200 10.1074/jbc.M000040200 10764737
49. Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. N Landman SY Jeong SY Shin SV Voronov G Serban MS Kang MK Park G Di Paolo S Chung TW Kim, Proc Natl Acad Sci USA 2006 103 19524 19529 10.1073/pnas.0604954103 17158800
50. Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. KH Cheung D Shineman M Muller C Cardenas L Mei J Yang T Tomita T Iwatsubo VM Lee JK Foskett, Neuron 2008 58 871 883 10.1016/j.neuron.2008.04.015 18579078
51. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. KN Green A Demuro Y Akbari BD Hitt IF Smith I Parker FM LaFerla, J Cell Biol 2008 181 1107 1116 10.1083/jcb.200706171 18591429